Introduction
============

Lung cancer is the leading cause of cancer-associated mortality worldwide. In 2015, an estimated 221,200 new cases (115,610 in men and 105,590 in women) of lung and bronchial cancer were diagnosed, and 158,040 deaths (86,380 in men and 71,660 in women) were estimated to occur as a result of the disease worldwide ([@b1-ol-0-0-11169]). Following diagnosis, only 16.8% of all patients with lung cancer live beyond 5 years ([@b2-ol-0-0-11169]). This is primarily attributed to the lack of early effective diagnostic measures and high recurrence rates. Approximately 50% of patients are diagnosed with advanced lung cancer, whose 5-year survival rate is \<15% ([@b3-ol-0-0-11169]--[@b5-ol-0-0-11169]).

Currently, molecular biomarkers are used to diagnose lung cancer. ProGRP, SCC-Ag, Cyfra21-1 and CEA are widely used as lung cancer serum biomarkers ([@b6-ol-0-0-11169]). However, a meta-analysis study reported that the sensitivity levels of ProGRP, SCC-Ag, Cyfra21-1 and CEA in the serum of patients with lung cancer were \<60% ([@b6-ol-0-0-11169]). Thus, investigating the molecular mechanism underlying tumorigenesis, and discovering new biomarkers can help improve diagnosis. In recent years, a number of high-throughput platforms, such as microarray technology, have been widely used to study gene expression during tumorigenesis. Now, a new approach combined with microarray technology and bioinformatics analysis allows the comprehensive analysis of gene expression changes in non-small cell lung cancer (NSCLC) ([@b7-ol-0-0-11169]--[@b9-ol-0-0-11169]).

In the present study, taking into account the microarray results of false positives, three mRNA microarray datasets were analyzed in order to investigate differentially expressed genes (DEGs) between NSCLC and normal tissue. Gene Ontology (GO) and pathway enrichment analysis were combined in order to identify functional DEGs, followed by protein interaction and survival analysis to identify hub genes in NSCLC.

Materials and methods
=====================

### Microarray data

The Gene Expression Omnibus (GEO; <http://www.ncbi.nlGSE18842m.nih.gov/geo>) is a public repository for the storage of data, such as microarray and next-generation sequencing data, which is freely available to users. The GEO database was used to obtain three gene expression profiles. GSE18842, GSE30219 and GSE33532 ([@b10-ol-0-0-11169]--[@b12-ol-0-0-11169]) were obtained from the GEO database. Experiments with the selected three datasets were performed in the Affymetrix Human Genome U133 Plus 2.0 Array microarray platform (GPL570; version 2.0; Affymetrix; Thermo Fisher Scientific, Inc.).

### Identification of DEGs

GEO2R ([@b13-ol-0-0-11169]) is an online interactive network tool that allows users to compare two or more sets of samples in order to identify the DEGs in a GEO data series. The results are presented as a table of genes ordered by significance. The present study used GEO2R to screen DEGs between NSCLC and normal lung samples. The adjusted P-values (adj. P) were used to correct the occurrence of false positive results. The adj. P\<0.01 and \|logFC\| \>1 were set as the cut-off criterion as an indicator of significance.

### GO and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis

The Database for Annotation, Visualization and Integrated Discovery (DAVID; version 6.7; <http://david.abcc.ncifcrf.gov>) is an online interactive tool that provides a comprehensive set of functional annotation tools for researchers to understand the biological meaning behind numerous different genes ([@b7-ol-0-0-11169]). The GO and KEGG pathway enrichment analysis panels in the DAVID were applied in order to identify DEGs. P\<0.05 was set as the cut-off criterion for indicating significance.

### Protein-protein interaction (PPI) network construction and module selection

The Search Tool for the Retrieval of Interacting Genes (STRING; <http://string.embl.de>) database was applied to construct a PPI network of DEGs ([@b14-ol-0-0-11169]). The confidence score ≥0.4 was set as the cut-off criterion. Subsequently, the Molecular Complex Detection (MCODE) panel in the Cytoscape software (version 3.7.2) was applied to screen significant modules in the PPI network ([@b15-ol-0-0-11169]). The degree cutoff=2, node score cutoff=0.2, k-core=2, and max.depth=100 were set as the cut-off criterion ([@b16-ol-0-0-11169]). The functional enrichment analysis of genes in the selected module was also performed by KEGG and GO panels in the DAVID.

### Survival analysis and protein expression in human NSCLC

Kaplan-Meier plotter (2018 version; <http://kmplot.com/analysis>) is an online, meta-analysis-based web tool that is used for biomarker assessment. The tool is capable of assessing the effect of 54,675 genes on survival rate using 10,461 cancer samples. The present study used this online tool to investigate the prognostic value of DEGs for patients with NSCLC in a large public clinical microarray database (<http://kmplot.com/analysis/index.php?p=service&cancer=lung>) ([@b17-ol-0-0-11169]).

Protein expression in NSCLC tissues and normal lung tissues was determined from The Human Protein Atlas (2018 version, [www.proteinatlas.org](www.proteinatlas.org)).

Results
=======

### Identification of DEGs

GSE18842 included 46 NSCLC samples and 45 normal samples. GSE30219 consisted of 229 NSCLC cancer samples and 14 healthy lung samples. The array data of GSE33532 included 80 NSCLC tissue samples and 20 normal samples. All samples were confirmed by histopathology. Based on the GEO2R analysis, a total of 3,153, 2,479 and 2,746 DEGs were identified from the GSE18842, GSE30219 and GSE33532 datasets, respectively. A total of 1,573 genes were screened out by taking an intersection of all three GEO datasets ([Fig. 1](#f1-ol-0-0-11169){ref-type="fig"}). Among them, 764 genes exhibited the same trend in expression, consisting of 428 upregulated and 336 downregulated genes in NSCLC tissues compared with normal lung tissues ([Table SI](#SD1-ol-0-0-11169){ref-type="supplementary-material"}).

### GO and KEGG pathway enrichment analysis

In order to further determine the function of DEGs, the present study used the DAVID for the functional and pathway enrichment analysis. The GO analysis revealed that upregulated DEGs were primarily involved in 'M phase' and 'cell cycle phase', while downregulated DEGs were primarily involved in 'plasma membrane part', and 'vasculature development'. Notably, the KEGG pathways analysis demonstrated that upregulated DEGs were enriched in the 'cell cycle', 'p53 signaling pathway' and 'DNA replication', ([Fig. 2A](#f2-ol-0-0-11169){ref-type="fig"} and [Table I](#tI-ol-0-0-11169){ref-type="table"}) while downregulated DEGs were enriched in 'vascular smooth muscle contraction', 'cell adhesion molecules' and 'tight junction' ([Fig. 2B](#f2-ol-0-0-11169){ref-type="fig"} and [Table I](#tI-ol-0-0-11169){ref-type="table"}). Overall, a total of 115 genes were enriched, including 68 upregulated DEGs and 47 downregulated DEGs ([Table SII](#SD1-ol-0-0-11169){ref-type="supplementary-material"}). The 115 genes were used for further PPI analysis.

### PPI network construction and modules selection

The PPI network of DEGs consisted of 51 nodes and 192 edges, including 33 upregulated and 18 downregulated genes ([Fig. 3A](#f3-ol-0-0-11169){ref-type="fig"}). Degrees ≥10 were set as the cut-off criterion ([Table SIII](#SD1-ol-0-0-11169){ref-type="supplementary-material"}). The top 10 genes were selected as hub genes, including cyclin-dependent kinase 1 (CDK1), checkpoint kinase 1 (CHEK1), budding uninhibited by benzimidazoles 1 (BUB1), replication factor C 4 (RFC4), polo-like kinase 1 (PLK1), RAD51 recombinase (RAD51), minichromosome maintenance complex component (MCM) 2, MCM4, MLF1 interacting protein (MLF1IP) and MCM6; all of which were upregulated. Furthermore, the most significant module was identified from the PPI network using the MCODE app, including 14 nodes and 85 edges ([Fig. 3B](#f3-ol-0-0-11169){ref-type="fig"}). The GO and KEGG pathway enrichment analyses revealed that genes in this module were significantly associated with 'mitotic cell cycle', 'DNA unwinding involved in DNA replication' and 'DNA replication pathway' ([Table II](#tII-ol-0-0-11169){ref-type="table"}).

### Survival analysis and protein expression in human NSCLC

The degree cutoff\>16, node score cutoff=0.2, k-core=2, and max.depth=100 were set as the cut-off criterion for PPI analysis, applied to predict PPI network of DEGs. The 6 genes were selected as core hub genes, including CDK1, CHEK1, BUB1, RFC4, PLK1 and RAD51. The prognostic value of the hub genes was evaluated using Kaplan-Meier plotter. The overall survival rate analysis demonstrated that high expression of CDK1 \[hazard ratio (HR), 1.84; 95% confidence interval (CI), 1.62--2.10; P\<1×10^−16^; [Fig. 4A](#f4-ol-0-0-11169){ref-type="fig"}\] caused the low overall survival rate for NSCLC, which was the same as PLK1 (HR, 1.66; 95% CI, 1.46--1.89; P=3.3×10^−15^; [Fig. 4B](#f4-ol-0-0-11169){ref-type="fig"}), RAD51 (HR, 1.84; 95% CI, 1.62--2.09; P\<1×10^−16^; [Fig. 4C](#f4-ol-0-0-11169){ref-type="fig"}), RFC4 (HR, 1.73; 95% CI, 1.52--1.97; P\<1×10^−16^ [Fig. 4D](#f4-ol-0-0-11169){ref-type="fig"}), BUB1 (HR, 1.21; 95% CI, 1.07--1.38; P=0.0025; data not shown), but not CHEK1 (HR, 1.42; 0.99--2.04; P=0.052; data not shown). HR\>1.5 and P\<0.05 were set as the cut-off criterion for the survival analysis. According to these cut-off criteria, four genes were identified as potential tumor markers for NSCLC, including CDK1, PLK1, RAD51 and RFC4. In order to determine the clinical relevance of hub gene expression, the present study then analyzed the expression of proteins from clinical specimens in The Human Protein Atlas database. The database indicated that CDK1 (P=1.03×10^−3^) was highly expressed in NSCLC compared with the low expression observed in normal lung samples, which was also true for PLK1 (P=4.73×10^−9^), RAD51 (P=2.93×10^−3^) and RFC4 (P=7.27×10^−4^) ([Fig. 5](#f5-ol-0-0-11169){ref-type="fig"}).

Discussion
==========

The development of NSCLC is a multi-step process that involves interactions between genetic, epigenetic aberrations and environmental factors, which leads to disorders of key oncogenes and tumor repressors ([@b1-ol-0-0-11169],[@b18-ol-0-0-11169]). Knowledge of the molecular mechanism underlying NSCLC is essential for diagnosis and treatment. The development of microarrays and high throughput sequencing techniques that can simultaneously detect mRNA expression levels of thousands of genes has benefited the prediction of potential diagnostic and therapeutic target genes for NSCLC ([@b10-ol-0-0-11169]). The present study extracted data from three gene expression profiles, GSE18842, GSE30219 and GSE33532. A total of 428 upregulated and 336 downregulated genes were identified between NSCLC samples and normal lung tissues. GO and KEGG annotations revealed that DEGs were enriched in the 'cell cycle', 'cell adhesion molecules' and 'tight junction'. Further PPI analysis, survival analysis and The Human Protein Atlas identified 4 hub genes that can be used as a tumor marker for diagnosis and prognosis or as a drug therapy target in NSCLC.

GEO2R ([@b13-ol-0-0-11169]) is an online interactive network tool used to identify the DEGs in GEO datasets. In the present study, a total of 764 DEGs were screened out between NSCLC samples and normal lung tissues with the GEO2R analysis, consisting of 428 upregulated and 336 downregulated genes. The GO and KEGG functional annotations revealed that upregulated DEGs were enriched in the 'cell cycle', 'p53 signaling pathway' and 'DNA replication', while downregulated DEGs were enriched in 'vascular smooth muscle contraction', 'cell adhesion molecules' and 'tight junction'. In accordance with Singhal *et al* ([@b19-ol-0-0-11169]), Voortman *et al* ([@b20-ol-0-0-11169]) reported that an imbalance of G~2~-M-phase arrest in the cell cycle can lead to the occurrence of NSCLC, which is one of its primary causes ([@b21-ol-0-0-11169]). Furthermore, the majority of NSCLC cases have p53 mutations and, as a result, an imbalanced expression of p53 target genes, such as p21, Bax and PUMA, which ultimately prompts the growth of tumor cells ([@b22-ol-0-0-11169]).

A total of 10 genes that had a high degree in the PPI network were selected as hub genes. The top 10 degree hub genes were as follows: CDK1, CHEK1, BUB1, RFC4, PLK1, RAD51, MCM2, MCM4, MLF1IP and MCM6. All these genes are upregulated in NSCLC. The GO and KEGG analyses revealed that the top 10 genes were enriched in 'mitotic cell cycle transition', 'ATP binding', and 'DNA replication'. It has been reported that the cell cycle checkpoint facilitated cellular responses to DNA damage, and an aberrant cell cycle facilitated the risk of cancer developing ([@b23-ol-0-0-11169]).

Survival analysis of the 10 genes revealed that selected hub genes were significantly associated with worse overall survival rate in patients with NSCLC, including CDK1, PLK1, RAD51 and RFC4. CDK1 is a member of the Ser/Thr protein kinase family ([@b24-ol-0-0-11169]). CDK1 was a master regulator of mitosis and meiosis, as a SUMO target both *in vivo* and *in vitro* involved in the initiation and transformation process through mitosis of the cell cycle ([@b25-ol-0-0-11169]). A number of studies have demonstrated that CDK1 inhibitors can block cell cycle progression through blocking mitosis and also have the potential to treat cancer due to their ability to control cell proliferation or inhibit tumor growth ([@b26-ol-0-0-11169],[@b27-ol-0-0-11169]). PLK1 belongs to the CDC5/Polo subfamily and is a Ser/Thr protein kinase ([@b28-ol-0-0-11169]). PLK1 is highly expressed during mitosis. PLK1 promotes cell proliferation and has also been observed to be upregulated in different types of human cancer. The deletion of PLK1 in cancer cells significantly inhibits cell proliferation and induces apoptosis ([@b28-ol-0-0-11169]). RAD51 was another selected hub gene. RAD51 is known to be involved in the homologous recombination and repair of DNA by interacting with the single stranded DNA-binding protein RPA and RAD52 ([@b29-ol-0-0-11169]). RAD51 is also involved in promoting tumorigenesis through interacting with BRCA1 and BRCA2, which are tumor suppressors ([@b30-ol-0-0-11169]--[@b32-ol-0-0-11169]). RFC4 is a member of the RFC family, which functions as a clamp loader that loads PCNA onto DNA and is involved in DNA repair activities ([@b33-ol-0-0-11169],[@b34-ol-0-0-11169]). Xiang *et al* ([@b35-ol-0-0-11169]) reported that RFC4 is upregulated in patients with colorectal cancer, which could predict its prognosis as it promotes cell proliferation and cell cycle arrest.

Due to the different selection methods and samples, the results of the present study were different from those of previous studies, which used the same lung cancer gene expression profiles (GSE18842, GSE30219 and GSE33532). Sanchez-Palencia *et al* ([@b10-ol-0-0-11169]) reported that KRT15 and PKP1, which may be good markers to distinguish squamous-cell carcinoma samples in GSE18842 ([@b10-ol-0-0-11169]). Rousseaux *et al* ([@b11-ol-0-0-11169]) reported that EBI3, PIWIL1, TPTE and NBPF4 may be potential biomarkers in lung cancer using the GSE30219 dataset ([@b11-ol-0-0-11169]). Meister *et al* ([@b12-ol-0-0-11169]) also reported that COL4A3, COL4A4 and CHRDL1 may be associated with lung cancer after analyzing the GSE33532 dataset ([@b12-ol-0-0-11169]). The present study revealed that four hub genes were significantly associated with worse overall survival of patients with NSCLC, including CDK1, PLK1, RAD51 and RFC4. To the best of our knowledge, RFC4 has not been reported as involved in the development of lung cancer before. RFC4 is involved in DNA replication as a clamp loader ([@b35-ol-0-0-11169]). In the present study, the results revealed that PLK1 and RFC4 were upregulated in NSCLC and were present in the cell cycle pathway, suggesting that the two genes may be important in the progression of NSCLC via the cell cycle pathway. Therefore, further experimental verification is required.

Overall, the present study provided a new comprehensive bioinformatics analysis to identify DEGs. The screened DEGs, including CDK1, PLK1, RAD51 and RFC4, can be used as tumor biomarkers for the diagnosis and prognosis, or as a drug therapy target, in NSCLC. However, further molecular biology experiments are required in order to confirm the underlying molecular mechanism of the genes identified in NSCLC.

There is a limitation to the present study. Heterogeneity within tumor cell populations is commonly observed in the majority of different types of cancer, particularly in lung cancer ([@b36-ol-0-0-11169]), which affects tumor growth rate, invasion and metastasis, and drug sensitivity and prognosis ([@b37-ol-0-0-11169]). NSCLC histopathology for the present study was confirmed by conventional paraffin-embedded tissue section, and the control samples were all from normal lung tissues, but not from their corresponding adjacent non-tumorous lung tissues. Fend *et al* ([@b38-ol-0-0-11169]) reported that the intrinsic heterogeneity of primary tissues in conventional paraffin sectioning with a mixture of various reactive cell populations can influence the results and interpretation of molecular studies. The authors also stated that a new technology called laser capture microdissection (LCM), is able to solve this problem ([@b38-ol-0-0-11169]). LCM is a powerful tool for isolating and studying the gene expression patterns of desired cells or tissues from heterogeneous populations ([@b38-ol-0-0-11169]). Isolation of a specific NSCLC cell from a heterogeneous tissue helps to obtain more meaningful molecular analysis results. Overall, the data from the present study suggested that data mining and integration analysis may be a useful tool for predicting cancer progression and understanding the molecular mechanisms underlying tumorgenesis.
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![Identification of differentially expressed genes in three expression profiling datasets GSE18842, GSE30219 and GSE33532.](ol-19-01-1008-g00){#f1-ol-0-0-11169}

![Enriched GO terms of differentially expressed genes in non-small cell lung cancer. DEGs were classified by GO analysis into three groups including biological process (blue), cellular component (red) and molecular function (green). (A) The number of genes upregulated for each functional classification. (B) The number of genes downregulated for each functional classification.](ol-19-01-1008-g01){#f2-ol-0-0-11169}

![PPI network of DEGs and modular analysis. (A) The Search Tool for the Retrieval of Interacting Genes/Proteins database was applied to predict the PPI network of DEGs. The PPI network of DEGs consisted of 51 nodes and 192 edges, including 33 upregulated genes and 18 downregulated genes. (B) The most significant module from the PPI network, including 14 nodes and 85 edges. All genes in this module were upregulated. PPI, protein-protein interaction; DEGs, differentially expressed genes.](ol-19-01-1008-g02){#f3-ol-0-0-11169}

![Prognostic value of hub genes in patients with NSCLC was investigated using a Kaplan-Meier plotter, assessing the overall survival rate of patients with NSCLC in specified hub gene^low^ and gene^high^ groups. The hub genes included (A) CDK1, (B) PLK1, (C) RAD51 and (D) RFC4. The Kaplan-Meier survival analysis revealed that patients with NSCLC that exhibited high expression levels of CDK1, PLK1, RAD51 and RFC4 had shorter overall survival rates. NSCLC, non-small cell lung carcinoma; HR, hazard ratio.](ol-19-01-1008-g03){#f4-ol-0-0-11169}

![Hub gene protein expression in human NSCLC specimens was determined from The Human Protein Atlas. Representative IHC images of hub gene protein expression in NSCLC tissues and normal lung tissues. Each lower panel is a enlargement of the outlined area in the top panel in its respective column in the same sample. The IHC analysis demonstrated that CDK1 was highly expressed in NSCLC compared with that in normal lung samples, which was also true for PLK1, RAD51 and RFC4. The IHC images were downloaded from The Human Protein Atlas. NSCLC, non-small cell lung cancer; IHC, immunohistochemistry.](ol-19-01-1008-g04){#f5-ol-0-0-11169}

###### 

GO and KEGG pathway enrichment analysis of upregulated and downregulated genes.

  \(A\) Upregulated                                                                          
  ----------------------- ----------------------------------------- ---------------- ------- --------------
  GO:0000279              M phase                                   48               12.8    1.00×10^−24^
  GO:0022403              Cell cycle phase                          53               14.1    1.30×10^−24^
  GO:0007049              Cell cycle                                69               18.4    5.70×10^−23^
  GO:0000087              M phase of mitotic cell cycle             38               10.1    8.10×10^−22^
  GO:0022402              Cell cycle process                        57               15.2    2.10×10^−21^
  GO:0005694              Chromosome                                46               12.3    2.20×10^−17^
  GO:0044427              Chromosomal part                          41               10.9    2.20×10^−16^
  GO:0000793              Condensed chromosome                      23               6.1     8.10×10^−14^
  GO:0000775              Chromosome, centromeric region            22               5.9     3.50×10^−13^
  GO:0043228              Non-membrane-bounded organelle            102              27.2    1.20×10^−9^
  GO:0005524              ATP binding                               51               13.6    3.00×10^−4^
  GO:0032559              Adenyl ribonucleotide binding             51               13.6    4.10×10^−4^
  GO:0030554              Adenyl nucleotide binding                 53               14.1    4.20×10^−4^
  GO:0001883              Purine nucleoside binding                 53               14.1    6.00×10^−4^
  GO:0001882              Nucleoside binding                        53               14.1    7.00×10^−4^
  KEGG:hsa04110           Cell cycle                                20               5.3     7.70×10^−11^
  KEGG:hsa04115           p53 signaling pathway                     11               2.9     4.20×10^−6^
  KEGG:hsa03030           DNA replication                           7                1.9     1.90×10^−4^
  KEGG:hsa00670           One carbon pool by folate                 5                1.3     4.70×10^−4^
  KEGG:hsa04114           Oocyte meiosis                            8                2.1     1.70×10^−2^
                                                                                             
  **(B) Downregulated**                                                                      
                                                                                             
  **Term**                **Function**                              **Gene count**   **%**   **P-value**
                                                                                             
  GO:0044459              Plasma membrane part                      84               27.5    1.70×10^−11^
  GO:0005886              Plasma membrane                           117              38.4    1.40×10^−10^
  GO:0001944              Vasculature development                   23               7.5     2.10×10^−10^
  GO:0001568              Blood vessel development                  22               7.2     8.40×10^−10^
  GO:0048514              Blood vessel morphogenesis                19               6.2     1.50×10^−8^
  GO:0007155              Cell adhesion                             32               10.5    6.40×10^−7^
  GO:0022610              Biological adhesion                       32               10.5    6.60×10^−7^
  GO:0003779              Actin binding                             20               6.6     2.20×10^−6^
  GO:0008092              Cytoskeletal protein binding              24               7.9     1.10×10^−5^
  GO:0050431              Transforming growth factor beta binding   5                1.6     1.40×10^−5^
  GO:0031226              Intrinsic to plasma membrane              44               14.4    2.20×10^−5^
  GO:0005887              Integral to plasma membrane               42               13.8    6.20×10^−5^
  GO:0009986              Cell surface                              19               6.2     8.20×10^−5^
  GO:0051015              Actin filament binding                    7                2.3     2.40×10^−4^
  GO:0032403              Protein complex binding                   12               3.9     4.40×10^−4^
  KEGG:hsa04270           Vascular smooth muscle contraction        9                3.0     1.20×10^−3^
  KEGG:hsa04514           Cell adhesion molecules                   9                3.0     3.50×10^−3^
  KEGG:hsa05414           Dilated cardiomyopathy                    7                2.3     7.90×10^−3^
  KEGG:hsa04530           Tight junction                            8                2.6     1.40×10^−2^
  KEGG:hsa05410           Hypertrophic cardiomyopathy               6                2.0     2.20×10^−2^

GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; has, homosapien.

###### 

Functional and pathway enrichment analysis of genes in the module.

  Pathway ID      Pathway description                         Gene count   False discovery rate   Nodes
  --------------- ------------------------------------------- ------------ ---------------------- ---------------------------------------------------------------------------------------
  GO.0000278      Mitotic cell cycle                          12           8.58×10^−12^           BLM, BUB1, CHEK1, MCM2, MCM4, MCM6, MLF1IP, ORC1, ORC6, PLK1, RFC4, TYMS
  GO.0044772      Mitotic cell cycle phase transition         9            2.87×10^−10^           CDK1, CHEK1, MCM2, MCM4, MCM6, ORC1, ORC6, PLK1, TYMS
  GO.1903047      Mitotic cell cycle process                  10           5.38×10^−9^            BLM, BUB1, CHEK1, MCM2, MCM4, MCM6, ORC1, ORC6, PLK1, TYMS
  GO.0000082      G~1~/S transition of mitotic cell cycle     7            1.74×10^−8^            CDK1, MCM2, MCM4, MCM6, ORC1, ORC6, TYMS
  GO.0006268      DNA unwinding involved in DNA replication   4            5.66×10^−8^            MCM2, MCM4, MCM6, RAD51
  GO.0005524      ATP binding                                 11           9.36×10^−8^            BLM, BUB1, CDK1, CHEK1, MCM2, MCM4, MCM6, ORC1, PLK1, RAD51, RFC4
  GO.0000166      Nucleotide binding                          12           1.62×10^−7^            BLM, BUB1, CDK1, CHEK1, MCM2, MCM4, MCM6, ORC1, PLK1, RAD51, RFC4, TYMS
  GO.0043168      Anion binding                               12           2.27×10^−7^            BLM, BUB1, CDK1, CHEK1, MCM2, MCM4, MCM6, ORC1, PLK1, RAD51, RFC4, TYMS
  GO.0003697      Single-stranded DNA binding                 4            3.14×10^−5^            BLM, MCM4, MCM6, RAD51
  GO.0005654      Nucleoplasm                                 14           6.79×10^−10^           BLM, BUB1, CDK1, CHEK1, MCM2, MCM4, MCM6, MLF1IP, ORC1, ORC6, PLK1, RAD51, RFC4, TYMS
  GO.0044454      Nuclear chromosome part                     7            8.90×10^−7^            BLM, BUB1, MCM2, ORC1, ORC6, PLK1, RAD51
  GO.0000228      Nuclear chromosome                          7            1.45×10^−6^            BLM, BUB1, CHEK1, MCM2, ORC1, ORC6, PLK1
  KEGG:hsa04110   Cell cycle                                  8            9.91×10^−13^           BUB1, CHEK1, MCM2, MCM4, MCM6, ORC1, ORC6, PLK1
  KEGG:hsa03030   DNA replication                             4            1.02×10^−6^            MCM2, MCM4, MCM6, RFC4

GO, Gene Ontology; KEGG, Kyoto Encylopedia of Genes and Genomes; has, homosapien.
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